Table 1 Demographic, clinical and treatment characteristics of women initiating trastuzumab for metastatic breast cancer between 1 October 2006 and 31 March 2014

From: Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)

  Trastuzumab pre-treated ( n =634) Trastuzumab-naive ( n =2565)
Patient characteristics at trastuzumab for MBC initiation
Age at first dispensing of trastuzumab for MBC, median (IQR) 56 (47–64) 59 (50–68)
Weight (kg) at first dispensing of trastuzumab for MBC, median (IQR) 71 (62–83) 70 (60–81)
HER2-positive by IHC 3+, patients (%) 148 (23) 1275 (50)
HER2-positive by ISH, patients (%) 497 (78) 1335 (52)
Median duration of (neo)adjuvant trastuzumab therapy (IQR), months 11.9 (9.5–12.7)
Hormone receptor-positive, patients (%)a 321 (51)
Deceased, patients (%) 334 (53) 1341 (52)
Treatment characteristics
Number of patients treated with first-line concomitant taxanes for MBC (%) 383 (60) 1705 (66)
Median number (IQR) of distinct chemotherapies dispensed following initiation of trastuzumab for MBC, per patient 2 (1–3) 2 (1–3)
Median time-to-initiation of trastuzumab for MBC from last (neo)adjuvant trastuzumab dispensing, months (IQR) 15.6 (6.5–28.6)
Median follow-up time from first dispensing of trastuzumab for EBC (IQR), months 66.9 (47.5–85.3)
Median follow-up time from first dispensing of trastuzumab for MBC (IQR), months 27.3 (13.9–43.7) 45.1 (23.6–68.4)
  1. Abbreviations: EBC=early breast cancer; IHC=immunohistochemistry IQR=interquartile range; ISH=in-situ hybridisation; MBC=metastatic breast cancer.
  2. aDispensing of an hormonal agent before initiation of trastuzumab for MBC indicated hormone receptor positivity.